(Q40259797)

English

Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue

scientific article published on June 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

object named as

Klaus Jung

5

1 reference

ORCID Public Data File 2021

author name string

Carsten Stephan

1

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Monika Jung

2

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Silke Rabenhorst

3

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Ergin Kilic

4

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

publication date

1 June 2015

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Clinical Chemistry and Laboratory Medicine

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

53

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

1109-1118

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Urine microRNAs as potential noninvasive biomarkers in urologic cancers.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

Phases of biomarker development for early detection of cancer

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

Individualized estimates of overdiagnosis in screen-detected prostate cancer

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

Suitable reference genes for relative quantification of miRNA expression in prostate cancer

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

A review of expression profiling of circulating microRNAs in men with prostate cancer

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

Changes in circulating microRNA levels associated with prostate cancer

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

PCA3: a molecular urine assay for predicting prostate biopsy outcome

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

Cell-free microRNAs: potential biomarkers in need of standardized reporting

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

Overdiagnosis and overtreatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

Potential Urinary miRNA Biomarker Candidates for the Accurate Detection of Prostate Cancer among Benign Prostatic Hyperplasia Patients

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

microRNA biomarkers in body fluids of prostate cancer patients

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization?

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

Robust microRNA stability in degraded RNA preparations from human tissue and cell samples

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

PCA3 gene expression in prostate cancer tissue in a Chinese population: quantification by real-time FQ-RT-PCR based on exon 3 of PCA3.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

Clinical use of novel urine and blood based prostate cancer biomarkers: a review

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

Primer: using decision analysis to improve clinical decision making in urology

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

Prostate-specific antigen screening in prostate cancer: perspectives on the evidence

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM-2014-1000

21 January 2018

Identifiers

10.1515/CCLM-2014-1000

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40259797&oldid=1891207447"